Aya Biosciences

Aya Biosciences was a private U.S. biotechnology company focused on differentiated psychedelic and plant-based therapeutics for neuropsychiatric and related conditions. The company described itself as a data-driven biodiscovery business developing botanical extractions, including rare cannabinoids, and entheogenic-based pharmaceutical formulations. Public descriptions of its early pipeline point to initial formulations for insomnia and pain, with additional development efforts in PTSD, substance use disorder, anxiety, sleep disorders, and other mental health indications. Aya appears to have remained at the preclinical or IND-enabling stage, with no confirmed clinical trials identified from the available public sources. Third-party databases now characterize the company as closed, although some corporate registry records still show the legal entity as active.